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rates in elderly steeply increase with age and the transition probabilities for speciﬁ c 
health states are age speciﬁ c, this population should be evaluated as non-homogeneous 
and over a lifetime with annual vaccinations. This study compares the cost results of 
ﬂ u vaccination between these two different modeling approaches. METHODS: Two 
models were developed to estimate the direct costs of annual ﬂ u vaccination compared 
with no vaccination: 1) a 1-year 65+ group cohort model; and 2) a lifetime multi-age 
cohort model with target population and clinical pathways stratiﬁ ed in ﬁ ve age cohorts 
(65–69 years; 70–74 years; 75–79 years; 80–84 years; 85+ years) eligible for annual 
vaccination. Both models were populated with US speciﬁ c data. Vaccination coverage 
and disease management were identical in both models. The decision tree included the 
following states: natural deaths, infected, and symptomatic states followed by GP 
visits, hospitalizations (pneumonia, inﬂ uenza, stroke, myocardial infarction, and con-
gestive heart failure), disease-speciﬁ c death rates, and recovery in nursing homes. 
Undiscounted costs per individual per year are compared for vaccinated and unvac-
cinated groups, using both approaches. RESULTS: The cost per individual per year 
is higher in the 1-year 65+ group cohort model versus the lifetime multi-age cohort 
model (no vaccination: $205 vs. $139; vaccination: $185 vs. $113) as expected: 
considering additional age cohorts with decreasing life expectancies in the multi-age 
cohort lowers the average cost per individual per year. Meanwhile, the selection of 
model type impacts the estimated incremental cost of vaccinated versus unvaccinated 
groups ($−20 vs. $−26). CONCLUSIONS: In economic assessments, a 1-year 65+ 
group cohort approach undervalues the impact of heterogeneity in elderly on the 
beneﬁ t of ﬂ u vaccination, and therefore, a lifetime multi-age cohort is preferred.
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OBJECTIVES: Several dynamic approaches can simulate epidemics and vaccination 
strategies. Generally, the models can be divided into top-down approaches like 
Markov models and differential equations and bottom-up approaches like cellular 
automata and agent-based models. Top-down approaches are characterized by cumu-
lative values that are representing groups of people. Bottom-up approaches, in con-
trast, consider individuals. Both approaches have advantages and disadvantages. 
Top-down approaches can be analyzed very well with mathematical methods, while 
bottom-up approaches require comparison of the outcome of simulation runs with 
different parameter sets. To improve validity of model structures, a method that 
compares different approaches for epidemic models is introduced. METHODS: Sta-
tistical calculations and Markov models are static, while other approaches like dif-
ferential equations or individual-based models are dynamic. In this context, dynamic 
does not only stand for simulation over time but also for models where the calculation 
of the next time step or period depends on the current state of the model. Since the 
transition matrices in Markov models are calculated before execution time, it is not 
considered to be dynamic. The advantage of dynamic models is that they can produce 
highly nonlinear behavior that cannot be reached with static calculations. To validate 
the structure of such nonlinear models, different model types are implemented and 
compared. Results are compared; sensitivity analysis is done separately. RESULTS: 
Outcome of vaccination against streptococcus pneumoniae was tested. a differential 
equations model and an agent-based model could reproduce results of published 
Markov models. As soon as we consider population dynamics, herd immunity, and 
serotype replacement, the Markov model was not able to fulﬁ ll the structural require-
ments anymore, while dynamic approaches still work. CONCLUSIONS: Dynamic 
models offer more information and opportunities for epidemic simulation. Usage of 
different approaches provides at least comparable reliability.
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OBJECTIVES: The aim of the current study was to determine inﬂ uenza vaccination 
rates among high- and non-high-risk adults across Europe (UK, France, Germany, 
Italy, and Spain). METHODS: Data from the 2008 EU National Health and Wellness 
Survey (NHWS) were used. Demographics, comorbidities, and vaccination behavior 
in the past year were assessed for all respondents. Health-related quality of life (SF-
12v2) and resource use (number of emergency room visits, hospitalizations, and physi-
cian visits) in the past 6 months were also measured. RESULTS: Only 23.7% of 
respondents received an inﬂ uenza vaccine in the past year (UK: 25.3%, Germany: 
25.2%, France: 20.2%, Italy: 24.8%, Spain: 24.1%). a total of 28,158 respondents 
(52.6%) were at high risk for inﬂ uenza complications (i.e., over age 50, had chronic 
conditions such as asthma, diabetes, COPD, cardiovascular conditions, or HIV/AIDS). 
Those at high risk reported signiﬁ cantly lower levels of both physical quality of life 
(mean = 45.88 vs. mean = 52.10) and health utilities (mean = 0.72 vs. mean = 0.73), 
and signiﬁ cantly higher levels of emergency room visits (mean = 0.21 vs. mean = 0.17), 
hospitalizations (mean = 0.22 vs. mean = 0.12), and provider visits (mean = 5.96 vs. 
mean = 4.14) in the past 6 months relative to those not at high risk, all P < 0.0001. 
Despite the signiﬁ cantly worse health proﬁ le, only 35.9% of high-risk respondents 
received the vaccine. High-risk status was the strongest driver of vaccination in the 
UK (high risk: 42.2% vaccinated vs. non-high risk: 5.4% vaccinated, Φ = 0.42) and 
the weakest in Germany (high risk: 31.8% vaccinated vs. non-high risk: 16.2% vac-
cinated, Φ = 0.18). The most common reason for nonvaccination was a belief that the 
vaccine was unimportant (35.9%). CONCLUSIONS: Despite inﬂ uenza vaccine rec-
ommendation guidelines, only a modest percentage of respondents in Europe were 
vaccinated. Even those at high risk for inﬂ uenza complications, who reported signiﬁ -
cantly worse health outcomes than non-high-risk respondents, were vaccinated at less 
than a 40% rate.
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OBJECTIVES: To perform a cost-effectiveness analysis of newborn universal vaccina-
tion against hepatitis B virus (HBV) and to identify the cost-effective affordability 
levels of the vaccination program in Vietnam. METHODS: We simulated a birth 
cohort using 1,693,000 newborns in 2002. Incremental cost-effective ratios (ICERs) 
per quality-adjusted-life-year (QALY) gained with universal newborn vaccination 
against HBV was calculated using a Markov model. Two types of analyses (including 
and excluding expenditure on the treatment of chronic hepatitis B and its complica-
tions) were performed. We used 5000 Monte Carlo simulations to examine the cost-
effectiveness acceptability and affordability of the vaccination program from the 
payer’s perspective and to derive a cost-effective affordability curve to assess the 
program’s cost and health effects. All costs were expressed in 2002 US dollars. 
RESULTS: In the base-case scenario, newborn universal vaccination against HBV 
reduced the carrier rate by 58% at a cost of US$42 per carrier averted. From the 
payer’s perspective, marginal cost per life-year and per QALY gained were US$4.76, 
much lower than GDP per capita of ~US$440 in 2002. The vaccination could be 
potentially affordable starting at a relatively low budget of US$1.7 million. Newborn 
universal vaccination would save US$ 1 billion from the treatment cost of complica-
tions due to chronic HBV infections. The probability of vaccination being both cost-
effective and affordable is 27% at an annual budget of US$4.1 million at the 
cost-effectiveness threshold of US$3.9 per QALY. CONCLUSIONS: Universal 
newborn vaccination against HBV is highly cost-effective in Vietnam. In low-income, 
high-endemic countries, where funds are limited and economic results of vaccination 
are uncertain, our ﬁ ndings on the cost-effectiveness affordability options would assist 
decision-makers in making proper health investments in vaccination strategies against 
HBV. 
POSTER SESSION I 
CANCER – Clinical Outcomes Studies
PCN1
TOLERABILITY OF FIRST-LINE TREATMENTS OF LOCALLY ADVANCED 
OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): A 
SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON
Edwards SJ1, Welton N2, Borrill J1
1AstraZeneca UK Ltd, Luton, Bedfordshire, UK; 2University of Bristol, Bristol, UK
OBJECTIVES: Platinum-based chemotherapy is a common ﬁ rst-line treatment of 
NSCLC; tolerability impacts on choice of regimen. This research compared the toler-
ability of geﬁ tinib and doublet chemotherapy in this setting in patients with activating 
epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations (M+). 
METHODS: Systematic searching of CENTRAL, EMBASE, and MEDLINE for ran-
domized controlled trials (RCTs) comparing ≥2 doublet chemotherapies (carboplatin 
or cisplatin in combination with either docetaxel, gemcitabine, paclitaxel, pemetrexed, 
or vinorelbine) for the ﬁ rst-line treatment of advanced NSCLC was completed in May 
2009. Data were extracted on the following grades 3/4/5 adverse events (AEs) most 
commonly reported with doublet chemotherapy or EGFR-TK inhibitors: anemia, 
diarrhea, fatigue, febrile neutropenia, nausea/vomiting, neutropenia, and rash. We 
performed a meta-analysis of the available geﬁ tinib versus paclitaxel/carboplatin RCTs 
in EGFR-TK M+ patients. We then carried out a mixed treatment comparison (MTC) 
of doublet chemotherapies in unselected advanced NSCLC patients using paclitaxel/
carboplatin as a baseline. Treatment effect for the risk of AE occurrence was estimated 
as an odds ratio (OR > 1.0 favors paclitaxel/carboplatin). RESULTS: Three RCTs were 
identiﬁ ed for geﬁ tinib, of which two were comparisons with paclitaxel/carboplatin. Meta-
analysis of these two trials gave the following statistically signiﬁ cant results: anemia—OR 
0.12, 95% conﬁ dence interval: 0.03–0.47; diarrhea—OR 5.78, 95% CI: 1.01–33.11; 
neutropenia—OR 0.01, 95% CI: 0.00–0.03. Twenty-nine trials were appropriate for 
inclusion in the MTC. The alternative doublet chemotherapy regimens did not demon-
strate a statistically signiﬁ cant reduction in risk of any of the AEs assessed versus paclitaxel/
carboplatin, with the exception of gemcitabine/cisplatin, which had a lower risk of febrile 
neutropenia (OR 0.39, 95% credible interval: 0.12–0.96). CONCLUSIONS: In the 
absence of RCTs comparing all doublet chemotherapies with geﬁ tinib in EGFR-TK 
M+ patients with advanced NSCLC, this adjusted indirect comparison suggests that 
geﬁ tinib may have important tolerability advantages over other ﬁ rst-line treatments 
in this targeted population.
